The potency-insolubility conundrum in pharmaceuticals: Mechanism and solution for hepatitis C protease inhibitors

The potency-insolubility conundrum in pharmaceuticals: Mechanism and solution for hepatitis C protease inhibitors

Publication: Biophysical Chem
Software: GastroPlus®

As compounds are optimized for greater potency during pharmaceutical discovery, their aqueous solubility often decreases, making them less viable as orally-administered drugs.

Relationships between the antidotal efficacy and structure, PK/PD parameters and bio-relevant molecular descriptors of AChE reactivating oximes: inclusion and integration to biopharmaceutical classification systems

Relationships between the antidotal efficacy and structure, PK/PD parameters and bio-relevant molecular descriptors of AChE reactivating oximes: inclusion and integration to biopharmaceutical classification systems

Publication: Expert Opin Drug Metab Toxicol
Software: ADMET Predictor®

The therapeutic outcome of oximes used as reactivators of phosphorylated human acetylcholinesterase (AChE) is influenced, among other factors, by their biological distribution, their in vivo ability...

In vitro-in vivo correlations: general concepts, methodologies and regulatory applications

In vitro-in vivo correlations: general concepts, methodologies and regulatory applications

Publication: Drug Dev Ind Pharm

The major objective of in vitro-in vivo correlations is to be able to use in vitro data to predict in vivo performance serving as a surrogate for an in vivo bioavailability test and to support biowaivers.

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function

Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function

Publication: Antimicrob Agents Chemother

Prolonged treatment with the oxazolidinone linezolid is associated with myelosuppression, lactic acidosis, and neuropathies, toxicities likely caused by impairment of mitochondrial protein synthesis (MPS). To evaluate the potential of the novel oxazolidinone tedizolid...

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics

Publication: Pharm Res
Software: MITOsym®

MITOsym, a new mathematical model of hepatocellular respiration and bioenergetics, has been developed in partnership with the DILIsym® model with the purpose of translating in vitro compound screening data...

Eslicarbazepine Acetate Monotherapy: A Population Ppharmacokinetic Analysis

Eslicarbazepine Acetate Monotherapy: A Population Ppharmacokinetic Analysis

Conference: American Epilepsy Society (AES)

Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED), approved by the US Food and Drug Administration for the treatment of partial-onset seizures (POS) as monotherapy or…

Relationship between exposure and efficacy of eslicarbazepine acetate monotherapy

Relationship between exposure and efficacy of eslicarbazepine acetate monotherapy

Conference: American Epilepsy Society (AES)

Eslicarbazepine acetate (ESL) is a once-daily, oral antiepileptic drug (AED), approved by the US Food and Drug Administration for the treatment of partialonset seizures (POS) as monotherapy or adjunctive...

Relationship Between Eslicarbazepine Exposure and Efficacy of Eslicarbazepine Acetate Adjunctive Therapy

Relationship Between Eslicarbazepine Exposure and Efficacy of Eslicarbazepine Acetate Adjunctive Therapy

Conference: American Epilepsy Society (AES)

Eslicarbazepine acetate (ESL; Aptiom®) is a novel once-daily (QD) oral antiepileptic drug, approved in then US, Canada and the EU as adjunctive treatment of partial-onset seizures (POS). ESL is extensively...

Relationship Between Eslicarbazepine Exposure and Safety Endpoints for Eslicarbazepine Acetate Adjunctive Therapy

Relationship Between Eslicarbazepine Exposure and Safety Endpoints for Eslicarbazepine Acetate Adjunctive Therapy

Conference: American Epilepsy Society (AES)

Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED), approved in the US, Canada and the EU as adjunctive treatment of partial-onset seizures (POS). After oral administration, ESL...

Relationship Between Eslicarbazepine Exposure and Safety Endpoints for Eslicarbazepine Acetate Monotherapy

Relationship Between Eslicarbazepine Exposure and Safety Endpoints for Eslicarbazepine Acetate Monotherapy

Conference: American Epilepsy Society (AES)

In two Phase III trials (093-045 and -046) of eslicarbazepine acetate (ESL) monotherapy in patients with partial-onset seizures (POS) uncontrolled by 1−2 antiepileptic drugs (AEDs), the incidence of...

Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model

Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model

Publication: Yao Xue Xue Bao
Software: GastroPlus®

This study is to establish physiologically based pharmacokinetic (PBPK) models of famitinib in rat and monkey, and then to predict the pharmacokinetics and tissue distribution of famitinib in human based on the PBPK models.

Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein

Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein

Publication: SAR QSAR Environ Res
Software: ADMET Predictor®

P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) are two members of the adenosine triphosphate (ATP) binding cassette (ABC) family of transporters which...

Novel Orally Swallowable IntelliCap(®) Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug

Novel Orally Swallowable IntelliCap(®) Device to Quantify Regional Drug Absorption in Human GI Tract Using Diltiazem as Model Drug

Publication: AAPS PharmSciTech
Software: GastroPlus®

Typically, colonic absorption of a drug is mandatory for a sustained release formulation to hold the drug's plasma level for more than 12 or 24 h above the minimum therapeutic plasma concentration (efficacy).

Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology to Improve in silico pKa Prediction

Best of Both Worlds: Combining Pharma Data and State of the Art Modeling Technology to Improve in silico pKa Prediction

Publication: J Chem Inf Model
Software: ADMET Predictor®

In a unique collaboration between a software company and a pharmaceutical company, we were able to develop a new in silico pKa prediction tool with outstanding prediction quality.